Shots:

• The P-III (Adhere) trial to evaluate lebrikizumab + TCS vs PBO in adult & adolescent patients aged 12 to ≤18yrs. with mod. to sev. AD
• The trial met its 1EPs & 2EPs i.e., @16wks., 75% change from baseline in the EASI score with reduction of two points from baseline, improvement in skin, itch relief, and QoL measured by EASI, pruritus NRS, sleep-loss due to pruritus, and DLQI, safety results were consistent with the 16wks. period of the two monothx. studies
• The company plans for additional data analyses from Adhere study along with results from the P-III (ADvocate 1/2) trials in 2022. Lilly and Almirall plans for the regulatory submissions in the US & EU in 2022

Ref: PR Newswire | Image: Lilly